Using patient's own cells

The safety of the proprietary adult stem cell technology using a patient's own (autologous) Mesenchymal Precursor Cells has been shown in Pilot Clinical Trials conducted in Australia . During the trials at The Royal Melbourne Hospital and the John Hunter Hospital , autologous MPC were isolated and grown up in culture using the proprietary platform technology.

For more information, please see:

http://mesoblast.com/mediareleases/news_mediareleases89.pdf  
and
http://mesoblast.com/mediareleases/news_mediareleases70.pdf

Product Development


 

Last Share Price

January 06 - Mesoblast Named 2009 North American Emerging Company By Frost And Sullivan

November 27 - Executive Director's Presentation at the AGM

November 27 - Chairman's speech to AGM

November 24 - Investor Briefing – The CEO Transcript

May 2008 - Issue Nine

September 2007 - Issue Eight

March 2007 - Issue Seven

August 2006 - Issue Six